KingMed Diagnostics Releases the First CSR Report in China's Third-Party Medical Testing Industry, Advancing Healthcare Equity with 20,000+ Medical Institutions

According to VCBeat (WeChat ID: vcbeat), on June 12, 2018, KingMed Diagnostics Group Co., Ltd., a pioneer and leader in China’s third-party medical testing industry, released its inaugural Corporate Social Responsibility Report, which is also the first such report in the industry.

KingMed Diagnostics Social Responsibility Report Launch Ceremony

Since its establishment, KingMed Diagnostics has established 37 medical laboratories and more than 2,000 logistics outlets, covering 90% of China’s population, serving over 20,000 medical institutions, and offering approximately 2,500 testing items……

This 80-page 2017 Corporate Social Responsibility Report marks the first formal disclosure of KingMed Diagnostics’ mission to support the Healthy China initiative. As a corporate citizen, KingMed Diagnostics leverages social forces, professional services, and leading technologies to collaborate with ecosystem partners in promoting the equalization of basic medical and health services, thereby facilitating the implementation of the Healthy China strategy.

Liang Yaoming, Chairman and CEO of KingMed Diagnostics, emphasized: “KingMed Diagnostics deeply understands the importance of corporate social responsibility. Starting from its core business as a professional third-party medical testing provider, the company has established an organized and institutionalized model for managing corporate social responsibility, integrating it as an organic component of corporate governance to drive sustainable and high-quality development for both the enterprise and the industry.”

“The health of the people is an important indicator of national prosperity and strength.” The report to the 19th National Congress of the Communist Party of China proposed “implementing the Healthy China Strategy” and called for “improving national health policies to provide comprehensive health services for the people.” To this end, China is embracing a holistic concept of public health and well-being, shifting the focus from disease treatment to people’s health, and continuously enhancing the health and well-being of its population.

Third-party medical testing is a crucial component of the socialized forces in healthcare services, serving as a beneficial supplement to China's existing medical resources. By providing comprehensive medical testing and pathological diagnostic services to medical institutions at all levels, it enhances clinical diagnosis and treatment standards while improving the utilization efficiency of societal medical resources. The report points out that KingMed Diagnostics has consistently aligned its development with the health and well-being of the people, participating in the construction of Healthy China and promoting the equalization of basic medical and health services.

In 2017, KingMed Diagnostics actively strengthened the development of its regional central laboratories. Leveraging its network of 37 medical laboratories, over 2,000 logistics outlets, and China’s first remote collaboration network for pathologists, KingMed’s service network has covered 90% of the population across China, serving more than 20,000 medical institutions. Meanwhile, KingMed further extended its service coverage to the county, township, and community levels, promoting the decentralization of medical resources to ensure equitable access to high-quality healthcare for all citizens. In 2017, KingMed partnered with local governments or medical institutions in 38 regions to establish regional clinical laboratory and pathological diagnosis centers, providing grassroots medical institutions with internationally standardized medical testing technologies and services. Additionally, KingMed established co-built medical laboratories in 34 poverty-stricken counties nationwide, helping to enhance the overall service level of regional and community healthcare.

In response to national policy initiatives, KingMed Diagnostics has also accelerated the expansion of its service network in remote western regions. In 2017, with the successive opening of Xinjiang KingMed and Qinghai KingMed, the company launched outsourced medical laboratory and pathological diagnostic services across all western provinces and autonomous regions, achieving network coverage in the vast majority of grassroots areas. KingMed organizes thousands of academic exchanges and technical training sessions annually for clinical, laboratory, and pathology professionals at grassroots medical institutions, nearly 30% of which are from grassroots medical facilities in western provinces, autonomous regions, and impoverished areas, thereby effectively making high-end medical testing and pathological diagnostic resources accessible to the grassroots population.

Liang Yaoming stated that participating in the implementation of the Healthy China Strategy and promoting the equalization of basic medical and health services is not only about enabling people at the grassroots level to access healthcare nearby and enjoy high-end, scarce, and high-quality medical services, but also about sharing the advancements in medical technology with them. To this end, KingMed Diagnostics remains committed to a clinical- and disease-oriented approach, leveraging its professional pathological diagnosis, medical testing services, and resource advantages to enhance the level of precision medicine and effectively manage national health. The company unswervingly fulfills its mission of providing Chinese patients with the latest technologies, improving nursing care standards, and enhancing patient outcomes, thereby comprehensively safeguarding public health.

Report data shows that KingMed Diagnostics keeps pace with international frontiers, continuously integrating multi-technology platforms around precision diagnostics. It has developed and applied 2,500 medical testing and pathological diagnosis projects for patients, healthcare providers, and health institutions, with the number increasing year by year, thereby providing comprehensive clinical diagnostic support and full-lifecycle diagnostic services.

To address the shortage of 90,000 pathologists in China, KingMed Diagnostics has established the country’s largest group of pathologists, comprising over 600 domestic and international experts. It also spearheaded the development of China’s first remote pathology collaboration network, partnering with regional medical institutions to deploy 150 remote pathology terminals. This initiative provides pathological diagnostic services to more than 13,000 medical institutions nationwide, alleviating the severe shortage of pathologists and enabling the sharing of pathological expertise.

As a leading third-party medical diagnostics enterprise that processes over 50 million test samples annually, KingMed Diagnostics has accumulated vast amounts of medical testing data covering diverse ages, regions, ethnicities, and populations. This data provides support for timely monitoring of epidemic trends, management of population health, and the advancement of precision medicine. Between 2016 and 2017, KingMed Diagnostics successively released big data reports on cervical lesions, renal pathology, vitamin D testing, cervical cancer screening for rural women, and mass spectrometry testing for inherited metabolic disorders.

As an industry leader, KingMed Diagnostics is committed to the sustainable development of the sector. By introducing internationally advanced medical laboratory testing technologies and service concepts, recruiting high-caliber domestic and international academic talent, and pursuing independent innovation, the company strives to drive technological innovation in the medical laboratory testing industry and share advanced testing technologies and knowledge with the broader sector.

The report reveals that, due to the late start of China’s third-party medical testing industry, KingMed Diagnostics has primarily pursued innovation through independent R&D and the introduction, digestion, and absorption of mature experiences and technologies from European and American medical laboratories, followed by secondary innovation. Through this development path, KingMed Diagnostics now possesses comprehensive diagnostic testing technologies and corresponding technical platforms covering nucleic acid detection, protein and metabolite detection, as well as histological, pathogenic microbial, and cellular and subcellular morphological detection.

By integrating various technology platforms, KingMed Diagnostics has established numerous clinical- and disease-oriented comprehensive laboratory diagnostic centers, thereby building its core technological system. In 2017, KingMed’s R&D investment reached RMB 255.9837 million, accounting for 6.75% of its operating revenue.

To enhance its scientific research and innovation capabilities, KingMed Diagnostics established the KingMed Academic Committee in 2017. Chaired by Academician Zhong Nanshan, the committee features Academicians Zeng Yitao, Chen Runsheng, and Hou Fanfan as advisors, along with 23 top domestic and international experts from the fields of laboratory medicine, pathology, and clinical practice. The committee is dedicated to the research and development, clinical translation, and industrialization of cutting-edge international technologies in laboratory medicine and pathology. It also vigorously promotes the development and application of biobanks, health big data, and AI-assisted diagnosis, collectively driving technological advancement in China’s medical testing industry.

Talent is the core driver of innovation. KingMed Diagnostics has made unremitting and sustained investments in cultivating high-caliber professionals in the fields of pathology and medical laboratory testing, providing enduring momentum for industry development. Each year, KingMed organizes thousands of academic conferences at various levels. By establishing platforms for academic exchange, it enhances opportunities for technical dialogue among industry professionals and promotes continuing education for healthcare workers, benefiting approximately 100,000 medical staff from nearly 10,000 healthcare institutions across China.

In addition to integrating corporate social responsibility into every aspect of its business development, KingMed Diagnostics has consistently upheld its public welfare commitments with professionalism. The report highlights that KingMed adheres to the vision of “Healthy China” and the principle of “Professional Public Welfare,” leveraging its technological and resource advantages to actively participate in community development and promote universal compassion. This is achieved through supporting community health initiatives, providing medical assistance to impoverished areas, offering free clinical consultations in communities, organizing voluntary blood donations, and coordinating various volunteer services.

KingMed Diagnostics has partnered with community and township health service institutions across its operational regions to actively undertake projects such as free pre-pregnancy checkups, “two-cancer” screening for women (cervical and breast cancer), newborn genetic metabolic disease testing, and chronic disease monitoring. For instance, since participating in the national rural women’s “two-cancer” screening program in 2009, KingMed Diagnostics had completed cervical cancer screening tests for over 4 million individuals across more than 19 provinces by December 2017. Through its “community and township service model,” KingMed Diagnostics continues to care for the health of local children and women, significantly reducing redundant infrastructure investments by community and township medical institutions, lowering costs, and decreasing government expenditure.

Looking ahead, Liang Yaoming stated that KingMed Diagnostics will continue to uphold its mission of “striving for human health, harmony, and a happy life.” With a strong sense of social responsibility, the company will actively participate in and support national healthcare reforms and a series of public health initiatives, contributing to the Healthy China strategy, safeguarding people’s well-being, and setting an industry benchmark.